Anthropic Acquires Biotech Startup Coefficient Bio for $400 Million

Anthropic has announced the acquisition of Coefficient Bio, a stealth AI-biotech startup, in a stock deal valued at over $400 million. The news was confirmed on April 3, 2026, marking the company's largest expansion beyond its core AI products to date.

Coefficient Bio had fewer than ten employees, but a strong team with backgrounds in computational biology. The startup focused on building AI models and agentic platforms for biological research and biopharma workflows. The entire team will now join Anthropic's newly established Healthcare and Life Sciences division.

The strategic intent is clear: Anthropic wants to position Claude as the preferred AI platform for drug discovery, clinical regulatory strategy, and biotech research broadly. This is a market where precision models and contextual understanding of complex scientific data matter enormously.

The acquisition comes closely after Anthropic established its Australian office and signed a memorandum of understanding with the Australian government on AI safety. The company is now rapidly expanding both its geographic footprint and vertical domain investments in parallel.

For CIOs and technology leaders in the healthcare sector, the signal is unmistakable: the major AI companies are moving from general-purpose models to industry-specific solutions, and biotech is one of the first places Anthropic is planting its flag.